ARTICLE | Financial News
On verge of global clinical trials, Just China raises $35M
June 8, 2018 4:45 PM UTC
Biologics company Hangzhou Just Biotherapeutics Ltd. (Hangzhou, China) raised $35 million in a series B plus round led by Hillhouse Capital. Existing investors Temasek, Lilly Asia Ventures, Arch Venture Partners, Taikang and BOCGI Zheshang Capital also participated.
Just China was founded in 2016 as a joint venture with Just Biotherapeutics Inc. (Seattle, Wash.), a company focused on streamlining and reducing the cost of antibody production. Both the U.S. and China affiliates use the same technology to build separate pipelines of biosimilars, developed in-house or in-licensed (see BioCentury Innovations, Sept. 1, 2016)...